Abstract

Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital‐based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblastoma. Our study identified 1173 patients from 0 to 19 years of age between 1998 and 2011. Comparisons were made among demographics, clinical characteristics, treatment, and survival variables. Fifty‐four percent of patients were over 10 years of age. Approximately 80% of patients underwent either partial or complete resection. Adjuvant therapy was used variably, and its use increased with patient age. Forty‐eight percent of patients received the combination of surgery, radiation, and chemotherapy, and 4% did not receive any treatment. As expected, patients ≤5 years of age had better 5‐year survival than those ages 6–10 (P = 0.01) or 11–19 years (P = 0.0077). Other factors associated with poor survival included black race and central tumor location. Better outcomes were associated with treatment that included surgery, radiotherapy, and chemotherapy compared to any other treatment combinations. Radiotherapy had no impact on survival in the 0 to 10‐year‐old age group, but was associated with improved survival for patients 11–19 years. We report an extensive demographic and survival analysis of pediatric glioblastoma. The observed differences likely reflect variances in tumor biology and likelihood of treatment receipt. Improved survival was associated with the use of surgery, radiotherapy, and chemotherapy. Radiation therapy was not associated with survival in patients younger than 10 years of age.

Highlights

  • Brain and central nervous system tumors are one of the leading causes of cancer death in children [1,2,3]

  • Pediatric glioblastoma is an aggressive high-­grade glioma associated with well-­established genetic subtypes with varying incidence, location, and outcomes based on general age categories [4]

  • Demographics We identified 1173 patients with from age 0 to 19 years from 1998 to 2011 in the National Cancer Database (NCDB), representing 1.15% of the total cases of glioblastoma (N = 101,846)

Read more

Summary

Introduction

Brain and central nervous system tumors are one of the leading causes of cancer death in children [1,2,3]. Pediatric glioblastoma (pGBM) is an aggressive high-­grade glioma associated with well-­established genetic subtypes with varying incidence, location, and outcomes based on general age categories [4]. H3F3A mutations at K27 occur and are associated with a marked dismal prognosis [5, 6]. IDH mutant and giant cell glioblastoma (GBM) predominate and primarily affect hemispheric locations. These subtypes have biologic, prognostic, and growth pattern differences that make pGBM markedly different from their adult counterpart [6, 7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call